Trilogy International Partners Inc, together with its subsidiaries, provides wireless voice and data communication services in Bolivia and New Zealand. The company's communications services include local, international long distance, and roaming services for customers and international visitors roaming on their networks. It also provides fixed broadband communications services to business and residential customers.
Read More…
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-425-4585900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$764.72 million
Profitability
Miscellaneous
Employees1,821
Next Earnings Date11/6/2019 (Confirmed)
OptionableNot Optionable
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners announced an annual dividend on Monday, April 15th. Investors of record on Monday, May 6th will be given a dividend of 0.02 per share on Monday, May 6th. This represents a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, April 15th. View Trilogy International Partners' Dividend History.
How were Trilogy International Partners' earnings last quarter?
Trilogy International Partners Inc (TSE:TRL) announced its earnings results on Monday, August, 12th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.02. The specialty pharmaceutical company earned $240.25 million during the quarter, compared to analysts' expectations of $245.08 million. View Trilogy International Partners' Earnings History.
When is Trilogy International Partners' next earnings date?
What price target have analysts set for TRL?
2 brokers have issued 12 month price objectives for Trilogy International Partners' stock. Their forecasts range from C$3.50 to C$3.50. On average, they anticipate Trilogy International Partners' stock price to reach C$3.50 in the next twelve months. This suggests a possible upside of 77.7% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.
Has Trilogy International Partners been receiving favorable news coverage?
Press coverage about TRL stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Trilogy International Partners earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Trilogy International Partners.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Medical Developments International (MVP), Eco Animal Health Group (EAH), BEXIMCO PHARMAC/S GDR REGS (BXP), Pharmaxis (PXS), Allergy Therapeutics (AGY), Futura Medical (FUM), Vita Life Sciences (VLS), Recce Pharmaceuticals (RCE), Patrys (PAB), Antisense Therapeutics (ANP), Avivagen (VIV), China Pharma (CPHI), Cathay International (CTI), Sareum (SAR) and NanoViricides (NNVC).
What other stocks do shareholders of Trilogy International Partners own?
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Chairman (Age 64)
- Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
- Mr. Erik Mickels, Sr. VP & CFO
- Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$1.97.
How big of a company is Trilogy International Partners?
What is Trilogy International Partners' official website?
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
